Conflicts of Interest – AZ

IN Rigged-Science

Just having a look at the Listed Conflicts on the AstraZeneca Trial Analysis Data 👀

(I mean you wouldn’t want Independent Researchers looking into it before it got mandated to the entire world or anything? “If the people who make it say it’s safe & effective, it must be safe & effective” – let’s just roll up our sleeves then)

  • Vaccitech is an Oxford University spin-out company that owns the biotechnology behind the AstraZeneca Vaccine.
    • The company was founded in 2016 as a University spin-off by Sarah Gilbert and Adrian V. S. Hill at the Jenner Institute, University of Oxford. 
    • Vaccitech has been financed and supported by Google Ventures (GV), Sequoia Capital, GeneMatrix, Liontrust Asset Management, Korea Investment Partners and Oxford Sciences Innovation (OSI).
  • International Trials sponsored by University of Oxford – lead by Andrew Pollard
  • Andrew Pollard (01)
    • Director of The Oxford Vaccine Group
    • Oxford Vaccine Group (OVG) who receive funding from vaccine manufacturers for their trials.
    • Member of WHO SAGE since 2016 (02)
    • Chair of UK health Dept. Vaccination Committee
    • Chair of The Joint Committee on Vaccination & Immunisation (JCVI) (03) who advises WHO & UK health departments on immunisation.
    • Lead developer of the Bexsero meningococcal B vaccine, previously owned by Novartis and now owned by GSK
  • Oxford University receives funding from Vaccine Manufacturing and Innovation Centre UK [20, p.81]. (04)
    • Oxford University Innovation (Hong Kong) Limited has entered into a joint venture with the Changzhou government in China.
    • Oxford University Innovation (Hong Kong) Limited has established a Sino-foreign joint venture in partnership with the Suzhou city government and Oxlink Investment Consulting Co. Ltd (Oxlink), Oxlink is a company registered in PRC.
    • Oxford University Innovation (Hong Kong) Limited has established a Sino-foreign joint venture in partnership with Shenzhen City Jinyucheng Science & Technology Co. Ltd (Jinyucheng), and Shenzhen City Guochuang Lianhe Science & Technology Investment Co. Ltd (Guochuang). Jinyucheng and Guochuang are companies registered in PRC.
  • Competing interests listed in the “Safety analysis” of the International trials of the AZ vaccine (05)

Financial Statements 2018/19 University of Oxford
Declared Competing-Interests in the AZ Trials Analysis

  • Oxford University – Oxford University has entered into a partnership with AstraZeneca for further development of ChAdOx1 nCoV-19. (08)
    • Oxford University could also collect a big windfall, as it holds a 5.4% stake directly. It also owns further stakes through the university’s spin-out holding company, Oxford Sciences Innovation (OSI). (09)
  • Alexander D Douglas – ADD reports grants and personal fees from AstraZeneca, outside of the submitted work. (10)
  • Pedro M Folegatti – Consultant to Vaccitech during the conduct of the study. (11)
  • Adam Finn – Member of the JCVI
    • Chair of the WHO European Technical Advisory Group of Experts.
    • Grants from Pfizer
    • Grants from GlaxoSmithKline
    • Grants from Sanofi
    • Grants from Merck Sharp & Dohme
    • Grants from Valneva. (12)
  • Sarah C Gilbert – co-founder of Vaccitech (collaborators in the early development of this vaccine candidate) and named as an inventor on a patent covering use of ChAdOx1-vectored vaccines and a patent application covering this SARS-CoV-2 vaccine (PCT/GB2012/000467). (13)
    • Prof Sarah Gilbert, scientist who led the team that created the Oxford/AstraZeneca coronavirus vaccine, is set for a payday of more than £20m as the biotech firm she co-founded prepares to float on the stock market in the US.
    • Gilbert owns 5.2% of Vaccitech, a Oxford University spin-out company that owns the biotechnology behind the AstraZeneca vaccine and others for MERS, hepatitis B, and a range of cancers. (14)
  • Catherine M Green – Clinical BioManufacturing Facility, University of Oxford, Oxford, UK.
    • During the COVID-19 pandemic Green was part of the Oxford team who developed the Oxford–AstraZeneca COVID-19 vaccine. (15)
    • Reports personal fees from the Duke Human Vaccine Institute, outside of the submitted work. (16)
  • Hill AVS – AVSH reports personal fees from Vaccitech, outside of the submitted work, and has a patent on ChAdOx1 licensed to Vaccitech (PCT/GB2012/000467), will from royalty income to the University of Oxford from sales of this vaccine by AstraZeneca and sublicensees. (17) Adrian Hill’s stakes could be worth £22m. (18)
  • Andrew J Pollard; Oxford COVID Vaccine Trial Group – Chair of the UK Department of Health and Social Care’s (DHSC) Joint Committee on Vaccination & Immunisation (JCVI)
    • Member of WHO’s SAGE
    • National Institute for Health Research (NIHR) Senior Investigator. (19)
  • Matthew D Snape – Grants from NIHR and non-financial support from AstraZeneca, during the conduct of the study
    • Grants from Janssen
    • Grants from GlaxoSmithKline
    • Grants from Medimmune
    • Grants from Novavax
    • Grants from MCM
    • Grants and non-financial support from Pfizer. (20)
  •  Johan Vekemans – employee of AstraZeneca. (21)
  •  Tonya L Villafana – named as an inventor on a patent application covering this SARS-CoV-2 vaccine.
    • A consultant to Vaccitech for an unrelated project, during the conduct of the study.
    • Employee of AstraZeneca. (22)

ANDREW POLLARD Prof

  • Lead developer of the Bexsero meningococcal B vaccine (23), previously owned by Novartis and now owned by GSK.
  • Chair of The Joint Committee on Vaccination & Immunisation (JCVI) (24), who advises UK health departments on immunisation.
  • Director of the Oxford Vaccine Group (OVG) (25), which received funding from vaccine manufacturers for their trials (26).
  • Professor of Paediatric Infection and Immunity at the University of Oxford, which has significant financial influence from Vaccine Manufacturing and Innovation Centre UK (27).
  • Was chair of the European Medicines Agency, Scientific Advisory Group of Vaccines (ASAGV) (28), whose main stakeholders are pharmaceutical industries (29).
  • In 2016, became a member of the World Health Organisation (WHO) Scientific Advisory Group of Experts (SAGE) (30)
  • Chaired the UK’s National Institute for Health and care Excellence (NICE) meningitis guidelines development group (31)
  • Developer in AstraZeneca Oxford COVID-19 Vaccine (32).

Declared Competing Interests in the AstraZeneca Trials Analysis

Declared Competing Interests in the AstraZeneca Trials Analysis

Declared Competing Interests in the AstraZeneca Trials Analysis

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Epub 2020 Dec 8. Erratum in: Lancet. 2021 Jan 9;397(10269):98. PMID: 33306989; PMCID: PMC7723445.

Oxford University

  • Oxford University – Oxford University has entered into a partnership with AstraZeneca for further development of ChAdOx1 nCoV-19. (33)
    • Oxford University could also collect a big windfall, as it holds a 5.4% stake directly. It also owns further stakes through the university’s spin-out holding company, Oxford Sciences Innovation (OSI). (34)

Alexander D Douglas

Pedro M Folegatti

Adam Finn

  • Adam Finn – Member of the JCVI
    • Chair of the WHO European Technical Advisory Group of Experts.
    • Grants from Pfizer
    • Grants from GlaxoSmithKline
    • Grants from Sanofi
    • Grants from Merck Sharp & Dohme
    • Grants from Valneva. (37)

Sarah C Gilbert

  • Sarah C Gilbert – co-founder of Vaccitech (collaborators in the early development of this vaccine candidate) and named as an inventor on a patent covering use of ChAdOx1-vectored vaccines and a patent application covering this SARS-CoV-2 vaccine (PCT/GB2012/000467). (38)
    • Prof Sarah Gilbert, scientist who led the team that created the Oxford/AstraZeneca coronavirus vaccine, is set for a payday of more than £20m as the biotech firm she co-founded prepares to float on the stock market in the US.
    • Gilbert owns 5.2% of Vaccitech, a Oxford University spin-out company that owns the biotechnology behind the AstraZeneca vaccine and others for MERS, hepatitis B, and a range of cancers. (39)

Catherine Green

  • Catherine M Green – Clinical BioManufacturing Facility, University of Oxford, Oxford, UK.
    • During the COVID-19 pandemic Green was part of the Oxford team who developed the Oxford–AstraZeneca COVID-19 vaccine. (40)
    • Reports personal fees from the Duke Human Vaccine Institute, outside of the submitted work. (41)

Adrian Hill

  • Hill AVS – AVSH reports personal fees from Vaccitech, outside of the submitted work, and has a patent on ChAdOx1 licensed to Vaccitech (PCT/GB2012/000467), will from royalty income to the University of Oxford from sales of this vaccine by AstraZeneca and sublicensees. (42) Adrian Hill’s stakes could be worth £22m. (43)

Andrew J Pollard

  • Andrew J Pollard; Oxford COVID Vaccine Trial Group – Chair of the UK Department of Health and Social Care’s (DHSC) Joint Committee on Vaccination & Immunisation (JCVI)
    • Member of WHO’s SAGE
    • National Institute for Health Research (NIHR) Senior Investigator. (44)

Matthew D Snape

  • Matthew D Snape – Grants from NIHR and non-financial support from AstraZeneca, during the conduct of the study
    • Grants from Janssen
    • Grants from GlaxoSmithKline
    • Grants from Medimmune
    • Grants from Novavax
    • Grants from MCM
    • Grants and non-financial support from Pfizer. (45)

Johan Vekemans

Tonya L Villafana

  •  Tonya L Villafana – named as an inventor on a patent application covering this SARS-CoV-2 vaccine.
    • A consultant to Vaccitech for an unrelated project, during the conduct of the study.
    • Employee of AstraZeneca. (47)

References[+]

Penny... on Health
Penny... on Health

DISCLAIMER: The information on this website is not medical science or medical advice. I do not have any medical training aside from my own research and interest in this area. The information I publish is not intended to diagnose, treat, cure or prevent any disease, disorder, pain, injury, deformity, or physical or mental condition. I just report my own results, understanding & research.